Anne Shah advises clients on health economic and outcomes research initiatives that support product commercialization and demonstrate client product/service value.

She has research experience in performing systematic literature reviews, designing and conducting health economic analysis of administrative claims and survey data, and developing economic/cost-effectiveness models for health technology assessments. Areas of research have included direct healthcare expenditures related to specific disease conditions—including COPD, endometriosis, and migraine—and medication adherence. Additionally, she has experience in pharmaceutical drug development and regulatory guidelines for generic drugs in the US and EU markets.

Anne has a PhD in pharmacoeconomics and health outcomes from Virginia Commonwealth University, an MPharm from Birla Institute of Technology & Science, Pilani, and a BS of pharmacy from Shri B.M. Shah College of Pharmaceutical Educational & Research, India.

Authored Content

New Avalere analysis evaluates the trends in baseline patient characteristics among Medicare fee-for-service beneficiaries with stand-alone Part D coverage who initiated a direct oral anticoagulant during the period 2013–2017.

ICER’s reliance on the average number of FDA drug approvals to calculate budget impact thresholds leads to significant variability.